Case Study

Meeting Enrollment Early With 100% Retention in a Phase 2 Migraine Study

At Tekton’s Yukon, Oklahoma site (now Oklahoma City), the team delivered a Phase 2 migraine treatment study with rapid startup, early enrollment completion, full participant retention, and near-perfect diary compliance. Participant education and proactive follow-up supported adherence throughout the study.

  • Enrollment goal met ahead of schedule
  • First participant visit within 48 hours of activation
  • 1.5 days from regulatory receipt to submission
  • 100% retention and near-perfect diary compliance

Episodic Migraine

About This Study

CLIENT
Biotech
TRIAL
Phase 2 migraine treatment study
SITE LOCATION
Yukon, OK (now Oklahoma City)

Partner With Tekton

Send us a synopsis or your I/E criteria. We'll respond with the Tekton sites and investigators we recommend, as well as site-level enrollment forecasts.

Complete the form on this page or email .

Submit Your Information